Can Chronic Hepatitis C Patients with Genotypes 2 or 3 Benefit from Shorter Interferon Treatment?
SUMMARY: A shorter 12 to 16 week course of pegylated interferon plus ribavirin is not as effective overall for people with chronic hepatitis C virus (HCV) genotypes 2 or 3, according to a meta-analysis and 2 recent international trials. However, abbreviated treatment may be a viable option for selected patients with rapid virological response at 4 weeks, low HCV viral load, and inability to tolerate longer therapy.
Related Questions
- Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C?
- Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C?
- Where can I find more information about management and treatment of patients with chronic hepatitis C?
